Serum amyloid A for predicting prognosis in patients with newly diagnosed Crohn’s disease

IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY
Qia Chen, Xi Zhang, Yizhe Tie, Jianwu Zhang, Pinwei Huang, Yuxuan Xie, Liqian Zhang, Xueer Tang, Zhirong Zeng, Li Li, Minhu Chen, Rirong Chen, Shenghong Zhang
{"title":"Serum amyloid A for predicting prognosis in patients with newly diagnosed Crohn’s disease","authors":"Qia Chen, Xi Zhang, Yizhe Tie, Jianwu Zhang, Pinwei Huang, Yuxuan Xie, Liqian Zhang, Xueer Tang, Zhirong Zeng, Li Li, Minhu Chen, Rirong Chen, Shenghong Zhang","doi":"10.1136/bmjgast-2024-001497","DOIUrl":null,"url":null,"abstract":"Objective Serum amyloid A (SAA) was found to be positively correlated with the activity of Crohn’s disease (CD); however, its prognostic value remains uncertain. Here, we examined its predictive ability in newly diagnosed CD and explored genetic association. Methods This retrospective cohort study included patients newly diagnosed as CD at the First Affiliated Hospital of Sun Yat-sen University between June 2010 and March 2022. We employed receiver operating characteristic curve, Cox proportional hazard regression models and restricted cubic splines to investigate the prognostic performance of SAA for surgery and disease progression. To assess possible causality, a two-sample Mendelian randomisation (MR) of published genome-wide association study data was conducted. Results During 2187.6 person-years (median age, 28 years, 72.4% male), 87 surgery and 153 disease progression events were documented. A 100-unit increment in SAA level generated 14% higher risk for surgery (adjusted HR (95% CI): 1.14 (1.05–1.23), p=0.001) and 12% for disease progression (1.12 (1.05–1.19), p<0.001). Baseline SAA level ≥89.2 mg/L led to significantly elevated risks for surgery (2.08 (1.31–3.28), p=0.002) and disease progression (1.72 (1.22–2.41), p=0.002). Such associations were assessed as linear. Adding SAA into a scheduled model significantly improved its predictive performances for surgery and disease progression (p for net reclassification indexes and integrated discrimination indexes <0.001). Unfortunately, no genetic causality between SAA and CD was observed in MR analysis. Sensitivity analyses showed robust results. Conclusion Although causality was not found, baseline SAA level was an independent predictor of surgery and disease progression in newly diagnosed CD, and had additive benefit to existing prediction models. Data are available upon reasonable request. The datasets generated for this study are available on request from the corresponding authors.","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjgast-2024-001497","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective Serum amyloid A (SAA) was found to be positively correlated with the activity of Crohn’s disease (CD); however, its prognostic value remains uncertain. Here, we examined its predictive ability in newly diagnosed CD and explored genetic association. Methods This retrospective cohort study included patients newly diagnosed as CD at the First Affiliated Hospital of Sun Yat-sen University between June 2010 and March 2022. We employed receiver operating characteristic curve, Cox proportional hazard regression models and restricted cubic splines to investigate the prognostic performance of SAA for surgery and disease progression. To assess possible causality, a two-sample Mendelian randomisation (MR) of published genome-wide association study data was conducted. Results During 2187.6 person-years (median age, 28 years, 72.4% male), 87 surgery and 153 disease progression events were documented. A 100-unit increment in SAA level generated 14% higher risk for surgery (adjusted HR (95% CI): 1.14 (1.05–1.23), p=0.001) and 12% for disease progression (1.12 (1.05–1.19), p<0.001). Baseline SAA level ≥89.2 mg/L led to significantly elevated risks for surgery (2.08 (1.31–3.28), p=0.002) and disease progression (1.72 (1.22–2.41), p=0.002). Such associations were assessed as linear. Adding SAA into a scheduled model significantly improved its predictive performances for surgery and disease progression (p for net reclassification indexes and integrated discrimination indexes <0.001). Unfortunately, no genetic causality between SAA and CD was observed in MR analysis. Sensitivity analyses showed robust results. Conclusion Although causality was not found, baseline SAA level was an independent predictor of surgery and disease progression in newly diagnosed CD, and had additive benefit to existing prediction models. Data are available upon reasonable request. The datasets generated for this study are available on request from the corresponding authors.
预测新诊断克罗恩病患者预后的血清淀粉样蛋白 A
研究发现,血清淀粉样蛋白 A(SAA)与克罗恩病(CD)的活动性呈正相关,但其预后价值仍不确定。在此,我们对其在新诊断的克罗恩病中的预测能力进行了研究,并探讨了其与遗传的关系。方法 该回顾性队列研究纳入了 2010 年 6 月至 2022 年 3 月期间在中山大学附属第一医院新诊断为 CD 的患者。我们采用接收者操作特征曲线、Cox比例危险回归模型和限制性立方样条来研究SAA对手术和疾病进展的预后表现。为了评估可能的因果关系,我们对已发表的全基因组关联研究数据进行了双样本孟德尔随机化(MR)。结果 在2187.6个人年(中位年龄28岁,72.4%为男性)中,共记录了87例手术和153例疾病进展事件。SAA水平每增加100个单位,手术风险增加14%(调整HR(95% CI):1.14 (1.05-1.23),p=0.001),疾病进展风险增加12%(1.12 (1.05-1.19),p<0.001)。基线 SAA 水平≥89.2 mg/L 会导致手术风险(2.08(1.31-3.28),p=0.002)和疾病进展风险(1.72(1.22-2.41),p=0.002)显著升高。这种关联被评估为线性关系。在预定模型中加入 SAA 可显著提高其对手术和疾病进展的预测性能(净再分类指数和综合判别指数的 p <0.001)。遗憾的是,在 MR 分析中没有观察到 SAA 与 CD 之间的遗传因果关系。敏感性分析表明结果可靠。结论 虽然没有发现因果关系,但基线 SAA 水平是新诊断 CD 患者手术和疾病进展的独立预测因子,并且对现有预测模型有额外的益处。如有合理要求,可提供相关数据。本研究产生的数据集可向相应作者索取。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Gastroenterology
BMJ Open Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
5.90
自引率
3.20%
发文量
68
审稿时长
2 weeks
期刊介绍: BMJ Open Gastroenterology is an online-only, peer-reviewed, open access gastroenterology journal, dedicated to publishing high-quality medical research from all disciplines and therapeutic areas of gastroenterology. It is the open access companion journal of Gut and is co-owned by the British Society of Gastroenterology. The journal publishes all research study types, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Publishing procedures are built around continuous publication, publishing research online as soon as the article is ready.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信